Identification | Back Directory | [Name]
DICHLOROTRICARBONYLRUTHENIUM (II) DIMER | [CAS]
22594-69-0 | [Synonyms]
CORM-2 Dichlorotricarbonylruthenium dimer Tetrachlorohexacarbonyldiruthenium Tricarbonyldichlororuthenium dimer TRICARBONYLDICHLORORUTHENIUM(II) DIMER DICHLOROTRICARBONYLRUTHENIUM (II) DIMER TRICARBONYLDICHLORORUTHENATE (II) DIMER ruthenium(II) tricarbonyl chloride dimer Dichlorotricarbonylruthenium(II) dimer,98% Dichlorotricarbonylruthenium(II)dimer,min.98% Dichlorotricarbonylruthenium(II) dimer, min. 98% | [Molecular Formula]
C6Cl4O6Ru2 | [MDL Number]
MFCD00011528 | [MOL File]
22594-69-0.mol | [Molecular Weight]
512.01 |
Chemical Properties | Back Directory | [Appearance]
Off-white to slightly yellow powder | [Melting point ]
208°C (dec.) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [solubility ]
Soluble in DMSO | [form ]
crystal | [color ]
off-white | [Water Solubility ]
Insoluble in water | [InChIKey]
JYHHJVKGDCZCCL-UHFFFAOYSA-J |
Hazard Information | Back Directory | [Chemical Properties]
Off-white to slightly yellow powder | [Uses]
Tricarbonyldichlororuthenium(II) dimer is used to enhance the coagulation and attenuation of vulnerability to fibrinolysis, modify thrombus growth or disintegration, enhances fibrinogen as a substrate for thrombin, and regulation of ion transport by gasotransmitters. Also used for various pharmacological studies. It is used as a CO donor for reactive oxygen species mediated bacterial killing. | [reaction suitability]
core: ruthenium reagent type: catalyst | [in vivo]
Tricarbonyldichlororuthenium(II) dimer (1-10 mg/kg; oral gavage; single dose) has a protective effect in a rat model of gastric mucosal injury induced by ischemia-reperfusion[3]. Animal Model: | Acute I/R gastric lesions treated male Wistar rats (250-300 g)[3] | Dosage: | 1, 5 or 10 mg/kg | Administration: | Oral gavage (i.g.); single dose | Result: | Significantly decreased the area of I/R gastric damage and significantly increased GBF at doses of 1 or 5 mg/kg.
Significantly increased mRNA expression of HMOX-1 but not HMOX-2 in gastric mucosa and significantly increased blood concentration at dose of 5 mg/kg.
Significantly increased gastric mucosal PGE2 content at dose of 5 mg/kg.
Significantly decreased mRNA expression of iNOS but not eNOS in gastric mucosa at dose of 5 mg/kg.
Significantly decreased 8-hydroxyguanozine (8-OHG) concentration in gastric mucosa at dose of 5 mg/kg.
Decreased the expression of pro- and anti-inflammatory markers' mRNA and proteins at dose of 5 mg/kg. |
|
|
Company Name: |
Alfa Aesar
|
Tel: |
400-6106006 |
Website: |
http://chemicals.thermofisher.cn |
|